Objective: To determine rheumatoid arthritis related out of pocket expenditure (OOPE) in Germany and to disaggregate the total OOPE into contributing cost domains. Methods: Data for the cost analysis were drawn from a multicentre randomised controlled prospective trial to assess the effectiveness of clinical quality management in patients with rheumatoid arthritis. Both payer sources and patient cost questionnaires were used to generate health care utilisation data. All cost domains of a recently published matrix were reviewed and potential sources of OOPE were determined. Health care utilisation data were developed throughout 2001. Co-payment regulations as per January 2004 were applied in order to indicate the most recent level of OOPE in Germany. Data were analysed in both physical and monetary units using descriptive statistics. Results: In all, 136 patients with rheumatoid arthritis were included. Mean total OOPE per patient and year was J417.20 (SEM 38.8, median 271.2). OOPE accounted for 15
P atient out of pocket expenditure (OOPE) covers an important part of total health care costs. Respective studies in the USA indicate that OOPE for deductibles, co-payments, and payment of uncovered services accounts for approximately 20% of total health care expenditure, with an increasing trend. 1 In particular, in patients with chronic conditions this results in a substantial burden for patients and their families. 2 3 Although the number of published reports on cost of illness in rheumatoid arthritis has increased considerably over the past decade, [4] [5] [6] most of the studies have applied a societal or a payer perspective and have not specifically addressed OOPE. Only few studies have examined OOPE in rheumatic conditions: Boonen et al 7 examined OOPE in 209 patients with ankylosing spondylitis and reported an average annual healthcare and non-healthcare expenditure of J431 per patient; Lapsely et al 8 reported particularly high OOPE for patients with advanced osteoarthritis, especially women in Australia; Lapsley et al 9 examined rheumatoid arthritis related OOPE in Australia and found an average annual spending of $A1513 (,J893; exchange rate as per July 2004: 1J = 0.59A$); in an early study by Liang et al, 10 the fraction covered by patient OOPE was estimated to account for at least 20% of total rheumatoid arthritis related direct costs; and finally, in a study by Cooper et al, 11 individuals with early inflammatory polyarthritis incurred a mean expenditure of £1297 over a six month period.
So far no data on rheumatoid arthritis related OOPE in a continental European country have been published. In addition, the composition of OOPE and the contribution of individual cost domains to the total OOPE is not clear. Thus the aim of our study was to determine the rheumatoid arthritis related OOPE in Germany and to disaggregate the total OOPE into the contributing cost domains.
METHODS
Original study and patient characteristics Data for the cost analysis were drawn from the findings of a multicentre randomised controlled prospective trial to assess the effectiveness of clinical quality management in patients with rheumatoid arthritis. 12 13 Inclusion criteria for the trial were: fulfilment of ACR classification criteria for rheumatoid arthritis 14 ; age over 18 years; having had at least one consultation with a rheumatologist; and insurance through the Allgemeine Ortskrankenkasse Niedersachsen (AOKN), a major statutory health insurance company. Written consent was required. Subjects were recruited by 14 outpatient rheumatologists in private practice in the state of Lower Saxony, Germany.
Both the clinical trial and the costing study involved collaboration between the AOKN, the Kassenärztliche Vereinigung Niedersachsen (KVN), and the Hannover Medical School. The AOKN is a health insurance organisation that covers medical care for 2.3 million members in Lower Saxony. The KVN is the regional physicians' association. The Social Ministry of Lower Saxony approved data transfer procedures and data protection measures. The study design was approved by the local ethics committee of the Hannover Medical School. Details of the approach are described elsewhere.
Generation of cost data
Two main sources of cost data were applied to determine the level of OOPE:
N Payer data sources (AOKN and KVN) were used to generate health care utilisation data for the period of January 2001 to December 2001. A patient per patient microcosting approach was carried out. 16 N In addition, a patient questionnaire was developed and applied. 17 The questionnaire was completed by patients at baseline and then once per quarter throughout 2001. The first form was filled in at the physician's office, and the following three questionnaires were sent by mail. A monitoring system was established to ensure that patients were reminded to return forms if necessary. Within the questionnaire, patients were instructed to report rheumatoid arthritis related health care utilisation only.
The cost analysis was structured according to the recently published matrix of cost domains in rheumatoid arthritis. 18 Based on the perspective of the study (patients' perspective) all cost domains were reviewed and potential sources of OOPE were determined. The identified sources of OOPE as well as the data sources applied to develop those data are given in table 1. It has to be noted that because of efforts to limit public health care expenditure, the co-payment regula- 
Sensitivity analysis and data management
In addition to the base case scenario a sensitivity analysistaking into account the range of possible co-payments (see the table 1)-was conducted for the following domains:
N Non-physician service utilisation: base case: co-payment J7.50; sensitivity analysis: low case co-payment J5; high case co-payment J10.
N Medication: base case: co-payment for all rheumatoid arthritis related drug treatment J7.50; sensitivity analysis: low case co-payment for all rheumatoid arthritis related drug treatment J5; high case: co-payment for disease modifying antirheumatic drugs (DMARD) J10; and for all other rheumatoid arthritis related drug treatment copayment J7.50.
N Devices and aids: base case: J7.50 co-payment; sensitivity analysis: low case co-payment J5; high case co-payment J10.
Data management was carried out on Microsoft ACCESS software (version 8.0). For data analysis SPSS version 10.0 was used. For the purpose of the current study only descriptive statistics were applied. 19 Data were analysed in both physical and monetary units.
RESULTS

Demographics and data collection
In all, 340 patients participated in the clinical trial. Health care utilisation questionnaires were sent to a randomly selected sample of 234 patients (67%). Over the course of the year 2001 four questionnaires (one per quarter) were distributed per patient; 227 patients returned at least one of the four questionnaires and complete sets of four consecutive questionnaires were returned by 136 respondents. The analysis was limited to those 136 patients. As has been shown previously in a sensitivity analysis, the exclusion of the remaining 91 patients who did not return all the questionnaires did not bias the reported health care utilisation. 17 The complete set of payer derived cost data (through AOKN and KVN) was generated and matched to the same sample of 136 patients. The patient flow is shown in fig 1. Demographic characteristics of the patient cohort included in the present study are shown in table 2.
OOPE per cost domain
The mean total OOPE per patient and year was J417.20 (SEM 38.8, median 271.2). A breakdown of total OOPE into the individual cost domains is shown in fig 2. The two most relevant cost domains were ''non-physician service utilisation'' and ''medication''.
Visits to physicians
Over the course of the year the 136 patients incurred a total of 3796 physician visits. The mean number of visits was 28 (SEM 1.7) per patient and year (median 23). In Germany a J10 co-payment is required only for the first physician visit per quarter. The respective data are given in table 3 (physical units) and table 4 (monetary units).
Non-physician service utilisation
In 2001 the patient cohort incurred a total of 3526 nonphysician service visits (mean (SEM), 25.9 (3.2); median 12.0). A subdivision into the various services used is given in table 3. The respective monetary units are displayed in table 4. The cost domain ''non-physician service utilization'' accounted for almost half the total OOPE (47%). Received cost questionnaire n = 234
Returned no questionnaire n = 7
Returned ≥ 1 and < 4 questionnaires n = 91
Returned all 4 questionnaires n = 136 Patients were included in cost study Figure 1 Algorithm for patients recruited for the cost study.
Medication
OOPE for medication was identified as the second most costly cost domain and accounts for 24% of total OOPE (table 4) . A subdivision into the various rheumatoid arthritis related drug classes as well as the respective physical consumption units is shown in table 3.
Devices and aids
In all, 93 devices and aids were used. The respective numbers (number of devices and aids used) per patient and year were: mean (SEM), 0.7 (0.1); median 0. The most frequently used aids and devices were: special footwear (n = 28), reconstruction work at home (n = 14), collar (n = 14), bandage (n = 11), and canes and crutches (n = 9).
Hospital facilities
Twenty patients (15%) incurred inpatient costs. The total number of inpatient days was 357. One patient had an inpatient episode of 58 days; all other inpatient episodes were less than 28 days. As co-payment is required only for a maximum of 28 days the total amount of co-payment was [357 days minus 30 days]6J10 = J 3270. The number of inpatient days per patient and year were: mean (SEM), 2.4 (0.6); median 0.
Transportation
In all, 334 transportation trips were employed. Only 27 patients (20%) incurred transportation trips. The data, however, appeared very skewed as three patients accounted for transportation costs of more than J1000 each, while the total amount of transportation costs for all patients was J7647.
Sensitivity analysis A sensitivity analysis was conducted for three cost domains: ''non-physician service utilisation'', ''medication'', and ''aids and devices''. Table 5 gives the data for ''non-physician service utilisation'' and ''medication''. The mean (SEM) for ''devices and aids'' were: low case, J3.40 (0.5); and high case, J6.80 (1.0).
DISCUSSION
Rheumatoid arthritis is a chronic disease with substantial total direct disease related costs, which amount to J2729 per patient and year from a societal perspective, with J417 (15.3%) being paid by the patients as OOPE (data presented in this study) and J2312 (84.7%) being covered by the payers.
16 Data from the United States indicate that OOPE account for at least 20% of the direct health care costs. 1 10 Our data from a German perspective indicate a slightly lower percentage (around 15%) of total direct health care costs that are covered by patients as OOPE. While our data showed a rheumatoid arthritis related OOPE of J417 per patient and year, recent estimates from Australia are also considerably higher ($A1513; ,J893). As none of the three studies mentioned 1 9 10 provides a detailed subdivision of the reported costs it is difficult to determine the reasons for the differences in OOPE. There is, however, evidence that the insurance coverage for health services is most comprehensive in countries like Germany and Switzerland, 20 which might explain a large part of that difference.
Within our study by far the most important OOPE cost domain is ''non-physician service utilisation''. This includes natural healers as well as psychological therapy, occupational therapy, physiotherapy, and balneotherapy. While it is well known that patients are willing to spend considerable amounts for complementary and alternative medical treatments, 21 the high OOPE for physiotherapy (J115 per patient and year) was unexpected. However, as recently shown in ankylosing spondylitis, similar values are observed at least in Belgium: the respective OOPE for physiotherapy was J102 per patient and year, accounting for 26% of total OOPE in that population. 7 Medication costs are by far the most important cost domain from a payer's perspective and account for J1019 per patient per year (44% of total direct rheumatoid arthritis related costs from the payer's perspective). 16 It is well known, that from a consumer perspective OOPE for medication is less dominant. 22 In our study, OOPE for medication resulted in J99 per patient and year (24% of total direct rheumatoid arthritis related costs from the patients' perspective). There are no published data that specifically address rheumatoid arthritis related OOPE for medication. However, our results are comparable to the reported OOPE of (J72 per patient and year; 18% of total OOPE) for medication in ankylosing spondylitis in Belgium. 7 Other domains, which each accounted for ,15% of total OOPE in our study, were ''visits to physicians'' (9% of total OOPE), ''hospital facilities'' (6% of total OOPE), ''transportation'' (13.5% of total OOPE), and ''devices and aids'' (1% of total OOPE). With regard to physician visits we identified a very low variance (SEM 0.6; SD 6.7), while the variance of transportation costs was very high (SEM 17.4; SD 202.9). Taking into account the skewed distribution pattern of transportation costs (three patients incurring costs of .J1000 per patient and year), the data within that cost domain have to be interpreted with caution .
Concerning co-payment, a major challenge is in the differentiation of rheumatoid arthritis v non-rheumatoid arthritis related co-payments. In the present study, we aimed to discriminate rheumatoid arthritis related from nonrheumatoid arthritis related co-payments. The total patient expenditure is therefore most probably underestimated.
Co-payment regulations as per January 2004 introduced the special recognition of patients with chronic illnesses such as rheumatoid arthritis. For those patients total co-payment per annum is limited to a maximum of 1% of their gross income. As we have no valid data of the patients' real household incomes in the cohort investigated, we could not estimate how many patients would have to contribute less than the calculated OOPE of J417. It is likely that patients with rheumatoid arthritis in Germany benefit from this new co-payment regulation.
During this study, some areas of interest were identified that require further research. First, generally speaking, all Western health care systems try to limit public expenditure. Transferring parts of the cost to the patients is a common tool for reducing the burden on public budgets. However, the extent to which such transfers affect the consumption of health care, and the elements involved (that is, essential versus non-essential healthcare), remains to be explored. Second, collection of patient co-payment data is a difficult task as the access to correct and comprehensive data through a single data source is impossible. We therefore had to rely on data from a variety of sources that included payer derived utilisation data as well as patient questionnaires. While it has been shown that patient questionnaires are valid and reliable tools for some specific cost domains, 17 it remains to be explored how valid and reliable are patients' reports of their own OOPE.
A limitation in the generalisability of the presented costing study is the selection of the study sample. The identification of patients was done by consultant rheumatologists-that is, all patients were receiving rheumatologist care. We did not examine OOPE in patients solely receiving general practitioner care. Furthermore, all patients had to be insured by the same health insurance scheme, the AOKN. We did not include patients covered by other insurance plans, or patients in the higher income strata who may be members of one of the private health insurance schemes. Finally, co-payment differs across countries owing to different health care systems, specific reimbursement systems, and obligatory premiums. Thus data from this study cannot be generalised, and comparisons of OOPE between countries should be made with caution.
Conclusions
Our study shows that rheumatoid arthritis is associated with substantial out of pocket expenditure, causing a considerable economic burden for patients with rheumatoid arthritis. The patients' out of pocket expenditure contributes significantly to the total health care expenditure in rheumatoid arthritis, and the patient perspective should be taken into account when calculating the overall direct costs of rheumatoid arthritis from a societal point of view. However, we are always looking for others, so do not let this list discourage you.
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